Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego
STOCKHOLM, SWEDEN – December 1, 2016. Modus Therapeutics AB, a clinical-stage drug development company focused on innovative treatments for patients with sickle cell disease (SCD), will present a poster at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego on 4th December. The ASH Annual Meeting is a world-leading event in malignant and non-malignant hematology.
The poster entitled: Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose Dependent Manner covers a study, focusing on microfluidic flow-based functional blood analysis, conducted by Modus Therapeutics in a research collaboration with Functional Fluidics LLC of Detroit in the U.S.
In patients with SCD it has been shown that the cause and continuation of vaso-occlusion are fueled by the sickle-red blood cells’ interactions with multiple other cell populations, promoting inflammation, obstructing the vasculature, and injuring the endothelium, leading to broad manifestations that affect most vital organs.
The data presented at ASH showed that sevuparin acts in a multicellular manner, blocking both firm adhesion by sickle red blood cells and L-selectin-mediated rolling adhesion of sickle-leukocytes, as well as functionally by interacting with another key adhesion receptor VCAM-1.
These results provide further insights into sevuparin’s multimodal action and its potential clinical benefits in treating the complex mechanisms manifested in vaso-occlusion and complications in SCD.
The poster will be presented on Sunday, December 4, 2016 18:00-20:00 in Hall GH at the San Diego Convention Center.
Sevuparin is currently being evaluated in a clinical PII study in acute vaso-occlusive crisis in hospitalized SCD patients (NCT02515838). In addition, Modus Therapeutics is planning to conduct a further clinical study to evaluate sevuparin for early treatment of symptoms of vaso-occlusion in an at-home setting.
For further information: Christina Herder, CEO, Tel: + 46 70 374 71 56, firstname.lastname@example.org
David Dible or Pip Batty, Citigate Dewe Rogerson, Tel: +44 207 282 2049/1022, email@example.com
About Modus Therapeutics AB
Modus Therapeutics is a clinical-stage drug development company developing new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in rare diseases with large unmet medical need. The Company’s most advanced candidate, sevuparin, is currently being evaluated in a Phase II clinical trial in sickle cell disease (SCD). Repeated painful crises in SCD, so called vaso-occlusive crises (“VOC”), leads to loss of vital organ function and often significantly reduced life span.
Modus Therapeutics is based in Stockholm. The Company’s major shareholders are KDev Investments AB (an investment fund jointly owned by Karolinska Development AB and Rosetta Capital), Östersjöstiftelsen (The Foundation for Baltic and East European Studies), and Praktikerinvest PE AB.
For more information, please visit www.modustx.com
Sevuparin is an innovative, disease-modifying proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions in SCD patients via a multimodal, anti-adhesive mechanism. The microvascular obstructions cause the severe pain during VOCs and the high morbidity through organ damage as well the risk of premature death.
Modus Therapeutics has received Orphan Drug Designation for sevuparin for use in SCD in the U.S. and EU.
About sickle cell disease
Sickle cell disease (SCD) is a painful, inherited blood disorder affecting millions of people around the globe and the most common inherited blood disorder in the U.S. affecting between 90,000-100,000 subjects, with medical care costs amounting to more than $1 billion. In Europe it is estimated that there are 35,000-40,000 SCD patients, and this number is higher in the Middle East and North Africa regions, with over 850,000 SCD patients.
There is currently no pharmaceutical product available that targets the underlying cause of VOCs that affect SCD patients. Current therapies are predominantly strong intravenous pain medications and SCD patients often have to be hospitalized in order to be treated.